Germany
Japan
United Kingdom
China
Antibodies
Download
USD 428.00
In Stock
USD 428.00
In Stock
TGF beta 1 (TGFB1) mouse monoclonal antibody, clone TB21, Azide Free
| Applications | ELISA, FN, IHC, WB |
| Reactivities | Human, Sheep |
| Conjugation | Unconjugated |
USD 379.00
In Stock
AFP Capture mouse monoclonal antibody, ELISA validated, clone OTI2E2
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Matched ELISA Pair | TA700014 |
USD 379.00
In Stock
purified CD5 Capture mouse monoclonal antibody, ELISA and Luminex validated, clone OTI10H3
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Matched ELISA Pair | TA700464 |
USD 415.00
2 Weeks
Trypsin (PRSS1) (immunoreactive) mouse monoclonal antibody, clone 4A7
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 440.00
2 Weeks
USD 379.00
In Stock
C Reactive Protein (CRP) mouse monoclonal antibody, clone C7
| Applications | ELISA, IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal iNOS Antibody (4E5)
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
TA336918 is a replacement of AM06772PU-N.
EGF mouse monoclonal antibody, clone S-21, Aff - Purified
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 379.00
In Stock
USD 415.00
In Stock
Trypsin (PRSS1) (immunoreactive) mouse monoclonal antibody, clone 2C4
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
MSMB mouse monoclonal antibody, clone YPSP-3, Purified
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
PD1 (PDCD1) mouse monoclonal antibody, clone 7C9, Aff - Purified
| Applications | ELISA, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 580.00
5 Days
hCG beta (CGB3) (beta 7 epitope) mouse monoclonal antibody, clone INN-hCG-68, Purified
| Applications | ELISA, R, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Active filters
Reactivities
- Human
Applications
- ELISA
Clonalities
- Monoclonal
Conjugates
- Unconjugated
Filter by
Target Symbol
- UCHL1 (124)
- LCN2 (112)
- IL6 (105)
- IL1RL1 (104)
- GFAP (100)
- S100A8/A9 (87)
- IL17A (85)
- D-DIMER (81)
- MPO (80)
- SAA1 (80)
- FABP3 (68)
- MYBPC3 (63)
- REG1A (62)
- NEFL (48)
- IGG4 (36)
- AMH (32)
- MAPT (24)
- NPPB (21)
- S100B (20)
- PDCD1 (18)
- CD80 (17)
- CD274 (13)
- MUC1 (13)
- PON1 (12)
- BRAF (11)
- F13A1 (11)
- FOLH1 (11)
- TNF (11)
- B2M (9)
- FSHB (9)
- IL2 (9)
- CCR5 (8)
- CSF2 (8)
- IFNG (8)
- KLK8 (8)
- MAP2K1 (8)
- MSMB (8)
- SERPINB3 (8)
- CD4 (7)
- CD5 (7)
- EGF (7)
- EGFR (7)
- LAG3 (7)
- PARVA (7)
- S100A1 (7)
- TP63 (7)
- AKT1 (6)
- CA12 (6)
- CCL2 (6)
- CD276 (6)
- CD52 (6)
- EFNA2 (6)
- ERG (6)
- FN1 (6)
- IL16 (6)
- MSLN (6)
- PSMD2 (6)
- VEGFA (6)
- CCL3 (5)
- CD1C (5)
- CXCL8 (5)
- ENG (5)
- ENO2 (5)
- EPHX1 (5)
- ERBB2 (5)
- H3-3A (5)
- MUC16 (5)
- NME1 (5)
- OTUB1 (5)
- PIK3AP1 (5)
- TLE1 (5)
- TMEM173 (5)
- WFDC2 (5)
- ALDH1L1 (4)
- AOC3 (4)
- CD33 (4)
- CD38 (4)
- CD44 (4)
- CRP (4)
- FGF2 (4)
- FGFR2 (4)
- FPR2 (4)
- HES1 (4)
- HPGD (4)
- IL10 (4)
- IL2RA (4)
- IL3RA (4)
- INSR (4)
- ITGB2 (4)
- KRT19 (4)
- LDLRAP1 (4)
- MAGEA3 (4)
- NOTCH2 (4)
- PRKCE (4)
- PXN (4)
- RBP4 (4)
- SLAMF7 (4)
- SOX17 (4)
- SPR (4)
- TNFRSF8 (4)
Antibody Hosts
Isotypes
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (40)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (9)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- Phospho-specific (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (1131)
- Secreted Protein (659)
- Transmembrane (287)
- ES Cell Differentiation/IPS (233)
- Protease (160)
- Transcription Factors (79)
- Protein Kinase (49)
- Stem cell - Pluripotency (39)
- Adult stem cells (14)
- Embryonic stem cells (11)
- Induced pluripotent stem cells (9)
- Stem cell relevant signaling - DSL/Notch pathway (6)
- Stem cell relevant signaling - JAK/STAT signaling pathway (6)
- Cancer stem cells (4)
- GPCR (4)
- P450 (3)
- Ion Channels: Other (2)
- Nuclear Hormone Receptor (2)
- Phosphatase (2)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (2)
- Stem cell relevant signaling - Wnt Signaling pathway (2)
Pathways
- Cytokine-cytokine receptor interaction (288)
- Pathways in cancer (176)
- Hypertrophic cardiomyopathy (HCM) (174)
- Jak-STAT signaling pathway (153)
- Toll-like receptor signaling pathway (148)
- Hematopoietic cell lineage (146)
- Graft-versus-host disease (132)
- Parkinson's disease (124)
- NOD-like receptor signaling pathway (121)
- Prion diseases (120)
- Cytosolic DNA-sensing pathway (111)
- MAPK signaling pathway (87)
- PPAR signaling pathway (74)
- Dilated cardiomyopathy (69)
- T cell receptor signaling pathway (69)
- Cell adhesion molecules (CAMs) (53)
- Amyotrophic lateral sclerosis (ALS) (52)
- Focal adhesion (52)
- Metabolic pathways (49)
- Prostate cancer (49)
- Chemokine signaling pathway (48)
- ErbB signaling pathway (47)
- TGF-beta signaling pathway (46)
- Endometrial cancer (43)
- Regulation of actin cytoskeleton (43)
- Melanoma (41)
- Natural killer cell mediated cytotoxicity (41)
- Colorectal cancer (39)
- Bladder cancer (38)
- Pancreatic cancer (37)
- Chronic myeloid leukemia (36)
- Glioma (36)
- Non-small cell lung cancer (36)
- Acute myeloid leukemia (35)
- Alzheimer's disease (35)
- Insulin signaling pathway (35)
- Fc epsilon RI signaling pathway (33)
- Progesterone-mediated oocyte maturation (33)
- Renal cell carcinoma (33)
- Neurotrophin signaling pathway (32)
- Type I diabetes mellitus (31)
- Autoimmune thyroid disease (30)
- Allograft rejection (29)
- GnRH signaling pathway (29)
- B cell receptor signaling pathway (28)
- Vascular smooth muscle contraction (27)
- Thyroid cancer (25)
- Long-term depression (24)
- Long-term potentiation (23)
- Fc gamma R-mediated phagocytosis (22)
- Neuroactive ligand-receptor interaction (22)
- Systemic lupus erythematosus (22)
- mTOR signaling pathway (22)
- Gap junction (20)
- Endocytosis (19)
- VEGF signaling pathway (18)
- Adipocytokine signaling pathway (17)
- Melanogenesis (16)
- Complement and coagulation cascades (15)
- Antigen processing and presentation (14)
- Oocyte meiosis (14)
- Type II diabetes mellitus (13)
- Viral myocarditis (13)
- Proteasome (12)
- RIG-I-like receptor signaling pathway (12)
- Tight junction (12)
- Apoptosis (11)
- Small cell lung cancer (11)
- Wnt signaling pathway (11)
- Regulation of autophagy (10)
- Dorso-ventral axis formation (9)
- Glycolysis / Gluconeogenesis (9)
- Epithelial cell signaling in Helicobacter pylori infection (8)
- Axon guidance (7)
- Cell cycle (7)
- Glutathione metabolism (7)
- Maturity onset diabetes of the young (7)
- Metabolism of xenobiotics by cytochrome P450 (7)
- Adherens junction (6)
- Arginine and proline metabolism (6)
- Nitrogen metabolism (6)
- Asthma (5)
- One carbon pool by folate (5)
- Purine metabolism (5)
- Pyrimidine metabolism (5)
- RNA degradation (5)
- Cysteine and methionine metabolism (4)
- ECM-receptor interaction (4)
- Folate biosynthesis (4)
- Notch signaling pathway (4)
- Pathogenic Escherichia coli infection (4)
- Arachidonic acid metabolism (3)
- Basal cell carcinoma (3)
- Cardiac muscle contraction (3)
- Citrate cycle (TCA cycle) (3)
- Leukocyte transendothelial migration (3)
- Spliceosome (3)
- Tyrosine metabolism (3)
- beta-Alanine metabolism (3)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (2)
- Caffeine metabolism (2)
- Cyanoamino acid metabolism (2)
- Drug metabolism - cytochrome P450 (2)
- Huntington's disease (2)
- Linoleic acid metabolism (2)
- Primary immunodeficiency (2)
- Renin-angiotensin system (2)
- Retinol metabolism (2)
- Starch and sucrose metabolism (2)
- Tryptophan metabolism (2)
- ABC transporters (1)
- Calcium signaling pathway (1)
- Hedgehog signaling pathway (1)
- Histidine metabolism (1)
- Non-homologous end-joining (1)
- Pentose phosphate pathway (1)
- Propanoate metabolism (1)
- Pyruvate metabolism (1)
- p53 signaling pathway (1)